Immunocore reports Q4 2025 KIMMTRAK sales of $104.5M, FY $400M; TEBE-AM data 2H 2026

Immunocore Holdings plc

2025-FY EPS reported -$0.71 revenue$400,016,000

Q4 2025 KIMMTRAK net sales $104.5M (+24% YoY); FY2025 $400.0M (+29% YoY).
FY2025 net loss narrowed to $35.5M from $51.1M in 2024; cash $864.2M.
R&D spend rose to $274.9M (FY2025) on autoimmune programs and Phase 3 trials.
TEBE-AM Phase 3 enrollment complete 1H 2026; topline OS data expected 2H 2026.
PRAME and HIV clinical data presentations expected 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.